Stryker Corporation $SYK Shares Sold by First Merchants Corp

First Merchants Corp reduced its holdings in Stryker Corporation (NYSE:SYK) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 58,744 shares of the medical technology company’s stock after selling 2,500 shares during the quarter. First Merchants Corp’s holdings in Stryker were worth $16,178,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in SYK. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in shares of Stryker by 1.2% during the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock valued at $880,000 after acquiring an additional 31 shares in the last quarter. Community Bank & Trust Waco Texas lifted its stake in Stryker by 2.3% in the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after acquiring an additional 31 shares during the period. Cornerstone Financial Management LLC boosted its holdings in Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. NWF Advisory Services Inc. boosted its holdings in Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after acquiring an additional 33 shares in the last quarter. Finally, Harold Davidson & Associates Inc. increased its position in Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after purchasing an additional 34 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Up 4.2%

SYK stock opened at $293.56 on Friday. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $392.55. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $112.60 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 1.78 and a beta of 0.78. The business has a 50 day moving average of $300.20 and a 200 day moving average of $312.98.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the company posted $3.13 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 14.95 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SYK. Citizens Jmp reduced their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $369.00.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.